Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22
Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
